Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...

In this article, we will look at where Royalty Pharma plc (NASDAQ:RPRX) ranks among the best affordable stocks to buy right now. The stock market appears to be at a turning point. While major ...

EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration ...